Data on novel DNA methylation changes induced by valproic acid in human hepatocytes

JarnoEJ Wolters*, SimoneGJ van Breda, SandraM Claessen, TheoMCM de Kok, JosCS Kleinjans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)

Abstract

Valproic acid (VPA) is a widely prescribed antiepileptic drug in the world. Despite its pharmacological importance, it may cause liver toxicity and steatosis. However the exact mechanism of the steatosis formation is unknown. The data presented in this DIB publication is used to further investigate the VPA-induced mechanisms of steatosis by analyzing changes in patterns of methylation. Therefore, primary human hepatocytes (PHHs) were exposed to VPA at a concentration which was shown to cause steatosis without inducing overt cytotoxicity. VPA was administered for 5 days daily to PHHs. Furthermore, after 5 days VPA-treatment parts of the PHHs were followed for a 3 days washout. Differentially methylated DNA regions (DMRs) were identified by using the 'Methylated DNA Immuno-Precipitation - sequencing' (MeDIP-seq) method. The data presented in this DIB demonstrate induced steatosis pathways by all DMRs during VPA-treatment, covering interesting drug-induced steatosis genes (persistent DMRs upon terminating VPA treatment and the EP300 network). This was illustrated in our associated article (Wolters et al., 2017) [1]. MeDIP-seq raw data are available on ArrayExpress (accession number: E-MTAB-4437). (C) 2017 The Authors. Published by Elsevier Inc.

Original languageEnglish
Pages (from-to)161-171
Number of pages11
JournalData in brief
Volume16
DOIs
Publication statusPublished - Feb 2018

Keywords

  • DNA methylation
  • Methylated DNA Immuno-Precipitation-sequencing (MeDIP-seq)
  • Primary human hepatocytes (PHHs)
  • Steatosis
  • Valproic acid (VPA)
  • MEDIP-SEQ

Cite this